Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

NCT01348087 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
148
Enrollment
INDUSTRY
Sponsor class

Stopped Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals